Guggenheim Maintains a Hold on Amgen Inc. (AMGN)

Amgen Inc. (NASDAQ:AMGN) is one of the best cheap stocks to buy for beginners. In a report released on September 5, Vamil Divan from Guggenheim maintained a Hold rating on Amgen Inc. (NASDAQ:AMGN), setting a price target of $288.00.

Amgen Inc. (NASDAQ:AMGN) reported its fiscal Q2 2025 earnings on August 5, with t0tal revenues increasing 9% to $9.2 billion compared to Q2 2024. GAAP earnings per share (EPS) rose 92% from $1.38 to $2.65, primarily attributed to higher revenues.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.